血小板生成素受体激动剂罗米司亭治疗急性放射病研究进展  

Research progress in the treatment of acute radiation sickness with thrombopoietin receptor agonist romiplostim

作　　者：杨馨 邢爽 余祖胤 YANG Xin;XING Shuang;YU Zuyin(School of Pharmacy,Bengbu Medical University,Bengbu,Anhui 233030,China;Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100850,China)

机构地区：[1]蚌埠医科大学药学院,安徽蚌埠233030 [2]军事科学院军事医学研究院,北京100850

出　　处：《军事医学》2024年第11期858-862,共5页Military Medical Sciences

基　　金：国家自然科学基金项目(81202147);国家科技重大专项(2018ZX09J18103-003)。

摘　　要：急性放射病(ARS)是指机体一次或短时间(数日)内分次受到大剂量射线照射引起的全身性疾病,而造血组织损伤是其基本损伤。罗米司亭(RP)是一种血小板生成素受体激动剂,通过刺激骨髓巨核细胞以促进血小板生成。近年研究表明,RP对ARS具有显著疗效,已被美国食品药品管理局批准用于治疗骨髓型ARS。该文主要就近年RP治疗ARS的药效学、药代动力学、作用机制和不良反应等研究进展进行综述。Acute radiation sickness(ARS)is a systemic syndrome caused by exposure to large doses of radiation in a single or short period of time.Hematopoietic tissue injury is the basic injury in case of acute radiation sickness.Romiplostim(RP)is a thrombopoietin receptor agonist that promotes platelet production by stimulating bone marrow megakaryocytes.In recent years,studies have shown that RP has a significant effect on acute radiation sickness,and has been approved by the United States Food and Drug Administration(FDA)for the treatment of bone marrow acute radiation sickness.In this paper,the recent research progress in the treatment of acute radiation sickness with romiplostim is reviewed.

关 键 词：罗米司亭 急性放射病 电离辐射 造血损伤 

分 类 号：R818.052.2[医药卫生—放射医学]